Biologics Biosimilars Therapeutic Peptides

Paras Biopharmaceuticals Finland Oy

Diabrid® Technology NobleCleav® Process Technology Technologies

Biologics Biosimilars Biomultifold® Therapeutic Peptides Eﬃcient Production

CyDisCo Product Technology APIs About Paras Biopharmaceuticals Finland Oy

Paras Novel Technologies

Paras Biopharmaceuticals is a fast growing biopharmaceutical Paras Biopharmaceuticals has developed multiple novel technology development company. Paras Biopharmaceuticals technologies. has successfully developed the propriety Diabrid Technology Platform for the high level expression of biosimilars and long 1. Diabrid Technology® therapeutic peptides in specially designed genetically stable 2. Noble Cleav® clones. 3. Biomultifold®

Paras Biopharmaceuticals is specialized in design, development and optimization of manufacturing technologies for Paras- Product offerings therapeutic peptides and soon to be off patent biologics. The company is building a robust portfolio of propriety technolo- Paras Biopharmaceuticals Finland have developed a number gies and has developed extensive intellectual property. Paras of products under the following categories. Biopharmaceuticals engages in the development and im- provement of biological processes and expression of recom- • Osteoporosis binant proteins in E.coli and P. pastoris. • Rheumatoid Arthritis Paras Biopharmaceuticals is a venture started in 2009 by a • Metabolic Disorders (Diabetes) team of scientists and technologists who have extensive re- • Oncology products search experience and skills in the development of biologics and biosimilar technologies. Paras Biopharmaceuticals gener- Paras products are in an advanced stage of development. ate value from innovative ideas based on scientific and tech- These include Teriparatide (osteoporosis), Anakinra (rheu- nological excellence to achieve quality products. matoid arthritis), and biosimilar diabetes long acting insulin (Glargine), and a rapid acting insulin (Aspart). There are other products in the Paras pipeline. Paras Concept

Paras Biopharmaceuticals was established with the vision Efficient Production of Biologics of using active synergy of academic expertise with proven industrial experience in bringing commercial scale protein production to market. Paras Biopharmaceuticals aims to Paras Biopharmaceuticals efficient production hosts -in bring workable innovative solutions to a range of problems. cluding E. coli. There are several advantages to use E. coli The business model for Paras Biopharmaceuticals is based as host organism. on technology development for biosimilars and their out- • Low cost licensing and work together in collaboration. • Rapid growth High biomass In Paras Biopharmaceuticals R&D we work on the principle • –“Why have complications, you can avoid? Rational design • Easy cultivation and manipulation of processes combining academic and industrial expertise • FDA friendly means increased efficiency without compromising quality. At Paras, our ultimate objective is to use innovative scientific ideas to make healthcare more affordable.

Worldwide Sales of Selected Therapeutic Peptides & Biosimilars (2010)

Glargine $ USD LANTUS Diabetes 4220M Novorapid Aspart ASPART Diabetes 2130M Ranibizumab LUCENTIS AMD 1560M Teriparatide FORTEO Osteoporosis 946M Exenatide BYETTA Diabetes 520M Anakinra KINERET Rheumatoid Arthritis 340M Enfuvirtide FUZEON HIV / AIDS 210M Pramlintide SYMLIN Diabetes 96M Paras Biopharma - Immediate Targets. mation. synthesis,gene assembly, cloning, andfinal product confir mid selection, optimal strain selection, bioinformatics,knowledgein codon utilization, oligo- sequence optimization advanced most latest scientificthe and technological and plas Paras Biopharmaceuticals on development based clone is Clone Development zation. port, including MS/ proteomics) and product API characteripurification development, analytical methods (detailed re timization, fermentation, optimization, product scale-up, Reports on cloning, cell line (clone) development, media op and optimized technology package including the following. bring products to market. Paras coreaimsstrengthspartners itsshortentototo timelines the provide to very robust ParasBiopharmaceuticals activelyisprovidelooking toits Technology Collaboration SDS- PAGE showing Glargine production and MS data the initial translational modification and of quality and consistencystructures,ary of validationcontrolappropriateandof post validationof the appropriate primary, secondary and terti shownbelow.Fullfingerprintingis protein the includesof tes product and an osteoporosis product of Paras portfolioThe SDS- PAGE and mass spectrometry analysis of a diabeParas products are extensively characterized and validated. Paras Product –Validation & Characterization expression through to the final product. 4100 4117.000 of Teriparatide. 4120 413 ------Core Strengths achieve the highest levels of production. periencedprovideto exceptional process development to greatestpossible economic value. Paras teamhighly is ex highesttheingproduction efficiencies. This facilitates the A robust upstream process development is critical in achiev Upstream Process Development • • • • • Core Strengths • most economic outcome. • • • Core Strengths robustness and cost savings. approach ensures, design process quality, by quality Our phycolumns and most advanced column packing systems. Parasteamhave extensive experience chromatograallof highestpurification efficiencies and qualityof the product. derstandingproteinofpurification, thereby achieving the Paras Biopharmaceuticals advanced un most utilizes the Purification Development on the market today. • for scale-up and large scale production. • • Sequences and product confirmations Documentation on clone development Plasmid selection Detailed report on codon optimization Codon optimization Achieve the highest purification efficiencies Scale-up and scale-down approaches in determining Minimizethe aggregation concepts in purification. Resin screening for the highest yields. Achieving the highest expression levels and production Development of the most suitable process parameters Selection and development of media in laboratory scale. . - - - -

Company ”Dedicated for Improved Healthcare”

For more details, write to us Paras Biopharmaceuticals Finland Oy www.parasbioharma.com Kurkelantie 5C-2, OULU FINLAND, 90230 email: [email protected]

Trademark Biomultifold Expression Technologies and Diabrid NobleCleav® Technologies are trademark of Paras Biopharmaceuticals Finland Oy.

Printed in Finland.